

Webinar 4: Present and future of gene therapy in nAMD and DR

21 November 2025

eLOS Platform – Virtual webinar

Time: 17:30 – 19:30 CET

ESASO Scientific Director: Mario Romano

Course Scientific Coordinators: Giuseppe Querques and Riccardo Sacconi

Session Chairman: Francesco Bandello (I)

Moderators: Giuseppe Querques (I) , Riccardo Sacconi (I)

Welcome and Introduction	Francesco Bandello (I)	<i>5 Min.</i>
Unmet needs in neovascular AMD and DR treatment		
The talk will be focus of actual unmet needs in the treatment of AMD and DR, focusing on the burden of injections and fluctuation of VEGF during the treatment that could influence the outcomes.	Reinier Schlingemann	<i>15 Min.</i>
Beyond actual treatments of nAMD and DR: the advantages of gene therapy		
An expert will present the advantages of gene therapy in comparison to actual treatments of nAMD and DR, as a solution of actual unmet needs.	Eric Souied	<i>15 Min.</i>
The “present” of gene therapy: different types available		
Several types of gene therapy are available. The talk will be focus on different types of gene therapy available to date.	Robert MacLaren	<i>15 Min.</i>
Discussion	All speakers <i>Moderators:</i> <i>Giuseppe Querques, Riccardo Sacconi</i>	<i>10 Min.</i>
Myths and truths about gene therapy		
There are many concerns about this therapy because it is little known. The different doubts and commonplaces will	Dominik Fischer	<i>15 Min.</i>

be addressed.

Different techniques for delivery of gene therapy: pros &
cons

The speaker will be present pro and cons of different techniques for the delivery of gene therapy.

Fabiana D'Esposito

15 Min.

Commercially available injectors and pearls and pitfalls of the surgical technique for subretinal delivery of gene therapy.

The speaker will focus on the technical aspects of commercially available injectors for the subretinal delivery of the vector, their pros and cons, as well as the surgical technique with pearls and pitfalls.

How to communicate about gene therapy: the language of patients

Paulo Stanga

15 Min.

It is not easy to communicate with patients how a gene therapy works, because it is not well known. The speaker will show how to communicate easily using a language suitable for patients, what clinical trials are available, benefits and risks of participating from clinical trials, clinical trial phases and chances of an investigational product reaching commercialisation.

Discussion

All speakers

Moderators:

10 Min.

Giuseppe Querques, Riccardo Sacconi

Take home message and closing remarks

Francesco Bandello

5 Min.

An application will be made to EACCME® for CME accreditation of this event.